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Abstract
Background: For respiratory allergic disorders in children, sublingual immunotherapy has been developed as an
alternative to subcutaneous immunotherapy. Sublingual immunotherapy is more convenient, has a good safety profile and
might be an attractive option for use in primary care. A randomized double-blind placebo-controlled study was designed
to establish the efficacy of sublingual immunotherapy with house dust mite allergen compared to placebo treatment in 6
to18-year-old children with allergic rhinitis and a proven house dust mite allergy in primary care. Described here are the
methodology, recruitment phases, and main characteristics of the recruited children.
Methods: Recruitment took place in September to December of 2005 and 2006. General practitioners (in south-west
Netherlands) selected children who had ever been diagnosed with allergic rhinitis. Children and parents could respond
to a postal invitation. Children who responded positively were screened by telephone using a nasal symptom score. After
this screening, an inclusion visit took place during which a blood sample was taken for the RAST test.
Results: A total of 226 general practitioners invited almost 6000 children: of these, 51% was male and 40% <12 years
of age. The target sample size was 256 children; 251 patients were finally included. The most frequent reasons given for
not participating were: absence or mildness of symptoms, absence of house dust mite allergy, and being allergic to grass
pollen or tree pollen only. Asthma symptoms were reported by 37% of the children. Of the enrolled children, 71% was
sensitized to both house dust mite and grass pollen. Roughly similar proportions of children were diagnosed as being
sensitized to one, two, three or four common inhalant allergens.
Conclusion: Our study was designed in accordance with recent recommendations for research on establishing the
efficacy of sublingual immunotherapy; 98% of the target sample size was achieved. This study is expected to provide useful
information on sublingual immunotherapy with house dust mite allergen in primary care. The results on efficacy and safety
are expected to be available by 2010.
Trial registration: the trial is registered as ISRCTN91141483 (Dutch Trial Register)
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Background
Specific immunotherapy with allergens might prevent the
onset of asthma in individuals with allergic rhinitis and
may accelerate the remission of asthma in children with
allergic disease. [1-3] Although subcutaneous immuno-
therapy (SCIT) is an effective treatment of respiratory
allergic disorders, [4] the injections can be uncomfortable
and side effects, though rare, may be serious and even
fatal. [5,6] The use of specific sublingual immunotherapy
(SLIT) for treatment of respiratory allergic disorders in
children may be a viable alternative to SCIT because of its
convenient form of administration and good safety pro-
file – which has allowed home administration of SLIT.
[7,8] Thus, although SLIT seems particularly suitable for
children in primary care, most clinical trials up to now
have been performed in a hospital setting.
Evidence for the efficacy of SLIT in children remains
inconclusive. Various reviews concluded that there was
insufficient evidence to recommend SLIT for use in rou-
tine clinical practice. [9-11] In their Cochrane review, Wil-
son et al. concluded that SLIT is an accepted treatment for
adults; studies with children revealed no significant reduc-
tion in symptoms and medication scores, but the number
of participants was small. [12]
In 2001, the Allergic Rhinitis and its Impact on Asthma
(ARIA) guidelines were published in co-operation with
the World Health Organization. [13] They recommend
treatment of allergic rhinitis in a stepwise manner (using
a combination of allergen avoidance, pharmacotherapy
and immunotherapy) based on the duration and severity
of disease, rather than on the type of exposure (i.e. sea-
sonal, perennial, occupational) as in previous guidelines.
[14] Immunotherapy is recommended for patients with
more severe disease, for those not responding to usual
treatments, or for those refusing usual treatments; this
type of patient is generally treated in a hospital setting
and/or by a specialist.
In the Netherlands, allergic rhinitis in children is usually
managed by the general practitioner (GP). We hypothe-
sized that SLIT could be an effective treatment in primary
care and designed a study to evaluate the efficacy and
safety of SLIT in children and adolescents with house dust
mite-induced allergic rhinitis. Here we describe the meth-
odology, recruitment, and main characteristics of the pri-
mary care study population.
Methods
Study design
This ongoing study is a randomized double-blind pla-
cebo-controlled study, comparing the efficacy of SLIT with
house dust mite allergen (SLIT-HDM) to that of placebo
treatment in 6 to 18-year-old children with allergic rhini-
tis and a proven house dust mite allergy in primary care.
Patients entered the study and started treatment either in
September-December 2005 or in September-December
2006 for a period of approximately two years. Written
informed consent was obtained. The study was approved
by the Ethical Review Board of Erasmus MC-University
Medical Center Rotterdam. The trial was registered as
ISRCTN91141483.
Participants and recruitment
GPs in south-western Netherlands selected children aged
6 to 18 years in their computerized patient files with
either a diagnosis of hay fever/allergic rhinitis or relevant
medication use: i.e. antihistamines for systemic use; nasal
corticosteroids; topical decongestants; topical anti-aller-
gics, and other nasal preparations.
Recruitment took place September to December in 2005
and in 2006. An information letter signed by the GP was
sent to the selected children. This letter described the gen-
eral purpose of the study, elicited cooperation, and pro-
vided a return form and envelope. On the return form
children and parents could indicate whether or not they
were interested in the study; if not interested they could
indicate the reason for not participating.
Participants who responded positively were telephoned
by a research assistant to arrange a screening interview
(see below). The research assistant asked questions about
nasal symptoms during the last three months, the history
of allergic rhinitis, general medication use, and use of
asthma medication. Table 1 gives an overview of all inclu-
sion and exclusion criteria.
After telephone screening an inclusion visit took place for
those who met the inclusion/exclusion criteria and who
agreed (children/parents) to further participation. During
this visit, the research assistant performed/recorded the
following: rhinitis symptoms during the last month and
last week (nasal symptoms: rhinorrhea, blocked nose,
sneezing, itching); conjunctivitis symptoms during the
last month and last week (eye symptoms: tearing, itching,
redness); International Study of Asthma and Allergies in
Childhood (ISAAC) questionnaire [15] for rhinitis and
asthma; wheeze and cough; family history of allergy,
asthma and eczema; rhinoconjunctivitis-specific quality
of life for pediatrics and adolescents (PRQLQ and AdolR-
QLQ[16,17]); blood sample for RAST (grass pollen, tree
pollen, HDM, cat dander and a pet, if present at home)
(CAP-Phadiatop®, Pharmacia Diagnostics AB, Uppsala,
Sweden); and physical examination (weight and height).
After the screening visit, when children met the inclusion
criteria and none of the exclusion criteria and children
and parents agreed to participate, a home visit was sched-BMC Family Practice 2008, 9:59 http://www.biomedcentral.com/1471-2296/9/59
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uled to provide instructions about the baseline diary.
Every day for one month, children recorded the symp-
toms related to allergic rhinitis on a diary card; also
reported were other complaints, rescue medication, and
other medication needed (see below). At this visit the
research assistant took dust samples from the child's bed-
room floor and mattress to assess indoor HDM exposure.
This will be repeated after two years.
After the baseline diaries had been completed a new visit
was scheduled and, after signing informed consent, partic-
ipants were assigned to SLIT treatment or placebo accord-
ing to the randomization schedule (see below).
Randomization
Randomization was generated by a computer program in
varying block sizes unknown to the investigators. The ran-
domization list was passed to the Department of Phar-
macy at Erasmus MC. In order to ensure that disease
severity was similar between patients assigned to verum
therapy and those assigned to placebo, randomization
was stratified according to severity on the basis of data
obtained during the telephone screening.
Intervention
Participants received an aqueous extract of house dust
mites (Dermatophagoides pteronyssinus) in a glycerinated
isotonic phosphate buffered solution (Oralgen Mijten,
Artu Biologicals, Lelystad, the Netherlands) or placebo
treatment consisting of the glycerol solvent. In accordance
with the manufacturer's guidelines the treatment period
was divided into two phases: a dose escalation phase of 20
days, and a maintenance phase of approximately two
years. Treatment started on day one with a single drop.
One drop consisting of 0.05 ml corresponds with 35 bio-
logical units (BU); the dose was increased by one drop per
day until day 20 (20 drops = 1 ml = 700 BU). The mainte-
nance dose was 20 drops (= 700 BU) twice weekly. The
drops were administered sublingually and kept there for
at least 1 minute before being swallowed. A research
assistant instructed the participants and also provided
written instructions. Participants, parents, investigators,
research assistants and caregivers were blinded to treat-
ment allocation.
Follow-up
Figure 1 shows the time schedule per individual patient.
After randomization children started with treatment for
20 days (dose escalation phase) followed by a mainte-
nance phase of two years. Children filled in a diary during
three months (between September and December) after
one and two years of treatment (see below). Every month
a research assistant completed a questionnaire (con-
ducted by telephone) throughout the entire study period.
Over the two years of treatment the total number of
planned contacts is 13 home visits and 23 telephone calls.
Outcome measures
The primary outcome measure for efficacy is the differ-
ence between the group receiving SLIT and the group
receiving placebo for the total daily mean rhinitis symp-
tom score for four nasal symptoms (see below), assessed
through a diary filled in during three months after two
years of treatment. In the period of evaluation (September
through December), the percentage of days on which the
daily symptoms are properly recorded should be at least
50%. For patients who do not meet this criterion in the
second year (e.g. dropouts after 1 year) data of the first
treatment year will be used. See section Data analysis for
further details.
Secondary outcome measures are the difference between
the group receiving SLIT and the placebo group for the
proportion of symptom-free days, the proportion of res-
cue medication-free days, use of rescue medication, mean
eye symptom score, total symptom score (nasal and eye
Table 1: Inclusion and exclusion criteria for the study population
Inclusion criteria
• aged 6–18 years
• history of allergic rhinitis for at least 1 year
• IgE antibodies ≥0.7 kU/l to house dust mite
• no use of nasal steroids in the month before start of baseline measurements
• rhinitis symptom score of at least 4 out of 12 during last 3 months
• signed informed consent
Exclusion criteria
• severe asthma 
(requiring 800 mcg budesonide daily or equivalent for other inhaled steroids; or requiring >3 courses of oral prednisone/prednisolone in 
previous year or required hospital stay for asthma in previous year)
• sensitization to pets present at home (IgE antibodies ≥0.7 kU/l)
• planned surgery of nasal cavity
• having received immunotherapy in past 3 years
• language barrier
• contraindications to sublingual immunotherapy (as supplied by the manufacturer)BMC Family Practice 2008, 9:59 http://www.biomedcentral.com/1471-2296/9/59
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Detailed time schedule per individual patient Figure 1
Detailed time schedule per individual patient.

Figure 1: Detailed time schedule per individual patient 
Letter to potentially eligible patients
(May – September)
Patient reply: willing to participate 
(if not: end)
Telephone screening
Screening visit (September)
Baseline visit (September-October)
baseline diary for 1 month 
Telephone contact (two weeks after visit)
Visit (October – November) Randomization and start SLIT ** 
treatment/placebo, dose escalation phase and maintenance phase
Monthly contact by telephone
(November/December until  August ) 
Visit (March- April) hand over new study medication, hand out 
diary  
Visit (August- September)  
 Daily filling in a diary for 3 months, hand over new study 
medication 
Visit (September –December)  
 Every month visit, last visit take diary 
Second year of the study has similar schedule as first year of study
*End first year of study*
*Start first year of study* 
** informed consent: 6-11 years child assents and parents consent 
                      12-17 years child assents/consents and parents consent BMC Family Practice 2008, 9:59 http://www.biomedcentral.com/1471-2296/9/59
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symptoms), and disease-specific quality of life after two
years of treatment. Overall evaluation of the treatment
effect will be assessed by patient, parents and research
assistant after two years of treatment.
Assessment of efficacy
Efficacy will be measured by patient-assessed symptom
scores. Although nasal, eye, skin and lung-related symp-
toms have been related to house dust mite allergy, the
main allergic symptoms are considered to be the follow-
ing nasal symptoms: sneezing, itching, watery running
nose and blockage. The intensity of these symptoms is
subjectively assessed according to a grading scale: 0 = no
complaints, 1 = minor complaints, 2 = moderate com-
plaints and 3 = serious complaints; the maximum score is
12. The scores will be assessed daily by the patient and
recorded in the patient's diary. The period of measure-
ment will be three months in the period September
through December in 2006 and 2007 for the primary out-
come measures (first cohort), and in 2007 and 2008 (sec-
ond cohort); this autumnal period of the year was chosen
because it has the highest HDM exposure levels.
Assessment of safety, tolerability and compliance
Adverse effects will be assessed by patients and parents
reporting effects in the diary, or calling the research assist-
ant with complaints, or by the research assistant via a
questionnaire filled in during home visits, and by
monthly telephone contact. All adverse events reported
during the study will be recorded. In case of serious
adverse events or persisting allergic symptoms after man-
agement according to protocol, the study treatment will
be discontinued for these patients. If patients discontinue
the study medication, they will be asked to agree to further
follow-up according to the study protocol during the
remainder of the study period.
Compliance will be measured by self-report of SLIT
administration in the diary and by monthly telephone
contact, and determined by weighing the returned study
medication.
Sample size calculation
As rhinitis symptoms are the primary outcome measure,
this was used for calculating the sample size. A Dutch
study on mattress covers provides relevant data for symp-
tom scores in patients with house dust mite allergy (aged
8–50 years). [18] Based on the baseline symptom score in
the latter study, and the ability to assess a reduction of at
least 30% (proposed by Malling as a clinically relevant
reduction) [19], in our study a sample size of 96 patients
per group would be required. Taking into account a drop-
out rate of 25% between randomisation and end of fol-
low-up, this would require 128 patients in each study
group. An alternative approach is assuming the nasal
score at the last week screening visit to be 4.5 (sd 2.6). A
30% change would provide a delta of approximately 0.5
(generally assumed to be clinically relevant) and require a
sample size of 105 per study group (alpha = 0.05 and beta
= 95%).
Quality of life
Rhinoconjunctivitis-specific quality of life will be assessed
through the validated Pediatric (6–11 years) and Adoles-
cent (12–17 years) Rhinoconjunctivitis Quality of Life
Questionnaire (PRQLQ and AdolRQLQ, respectively) at
baseline and after one and two years. [16,17] To establish
the presence of lower airway symptoms during the last 12
months at baseline, specific questions on wheezing and
dry cough at night were taken from the ISAAC. [15]
Rescue medication
During the study the use of symptomatic allergy medica-
tion is discouraged, especially use of long-acting antihista-
mines and locally or generally administered
corticosteroids. However, rescue treatment is allowed in
case of persisting allergic symptoms (levocetirizine tab-
lets, xylomethazoline nasal spray and levocabastine eye
drops); the above-mentioned rescue medication will be
provided free of charge. In principle, patients are encour-
aged to use the provided medication only, but are allowed
to use their own medication as well. Patients were clearly
instructed on the use of rescue medication and other med-
ication, and on how to document entries in the patient
diary. For severe or steadily worsening rhinoconjunctivitis
symptoms or intermittent asthma the patient should con-
sult his/her physician.
Data analysis
The treatment effect will be tested at a two-sided signifi-
cance level of 5%. Statistical comparison between verum
and placebo of the mean daily sum score from the diary
after two years will be done using Analysis of Covariance.
There will be three covariates in this analysis: baseline
nasal sum score at entry into study, age of patients, and
presence of cat allergy. In case more than one child from
the same family has been included in the study and con-
tribute to the final analysis, we will test whether 'family'
provides a statistically significant effect (P < 0.20). In that
case 'family' will be added as a random effect.
Exploratory subgroup analyses are planned for the differ-
ence between placebo and verum regarding the primary
outcome according to age and the baseline symptom
score (both dichotomized at the median value).
All analyses will be performed according to the intention-
to-treat principle, i.e. irrespective of compliance with the
prescribed dosing schedule and other treatments, but
excluding patients in whom major inclusion criteria wereBMC Family Practice 2008, 9:59 http://www.biomedcentral.com/1471-2296/9/59
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not fulfilled. A per-protocol analysis will include all
patients who took at least 80% of the study medication
and completed 50% of the diaries.
For this paper, the distribution of age and gender through-
out the recruitment period will be compared. All data are
presented as summary descriptive statistics: means, stand-
ard deviations (SD) or percentages. Statistical analyses
were carried out with SPSS version 11.0 and differences of
p < 0.05 were considered significant.
Results
Letters were posted by 226 general practitioners to 5986
children. An answer form was returned by 2555 children;
of these, 1072 children responded positively to the letter
and 500 of these children were included after the screen-
ing by telephone. Finally, 251 children (i.e. only 4.2% of
the children selected in general practice) were included in
the study.
Table 2 summarizes the main reasons given for not partic-
ipating in the consecutive recruitment phases. In response
to the initial mailing most of those who declined had few
or no complaints (48%), or had another allergy (16%).
During the telephone screening, those not included had
no history of HDM allergy (28%) or a low symptom score
(28%). In the last phase of the recruitment (the screening
visit) the main reasons for non-participation were no
HDM allergy but only grass or tree pollen allergy detected
by RAST (33%), and no sensitization to inhalant allergens
detectable by RAST (30%).
Table 3 presents the baseline characteristics of the
included patients. The mean age of the participants was
11.8 (SD 3.0) years. A total of 251 children were rand-
omized to treatment or placebo. During the recruitment
period nasal complaints were assessed at several time
points; this symptom score showed a difference between
telephone screening (6.8) and screening visit (4.5). More
than half of the children reported wheeze/breathlessness
(54%) and dry cough (53%) during the last year. In
almost 37% of the children asthma was reported.
The majority of the children (77%) were multisensitized.
Roughly similar proportions of children were diagnosed
as being sensitized to one, two, three or four common
allergens. Of the included children, 71% was sensitized to
both HDM and grass pollen, followed by tree pollen in
43%, and cat dander in 34% of the children.
Table 4 shows the distribution of age and gender during
the recruitment process. Of almost 6,000 children, 51%
Table 2: Reasons not to participate in the consecutive recruitment phases
Reasons not to participate Total
(n)
Percentage
Letter returned (n = 1483)
Few or no complaints 710 48.4%
Other allergy 240 16.4%
Study too burdensome 202 13.8%
No interest in the study 186 12.6%
No reason 145 9.8%
Telephone screening (n = 572)
No HDM allergy 159 27.8%
Low symptom score (<4/12) 158 27.6%
Not interested in study 57 10.0%
Severe asthma 39 6.8%
Language barrier 27 4.7%
Use of immunotherapy in the last 3 years 19 3.3%
Refusing blood sample to be taken 17 3.0%
Age (out of range) 15 2.6%
Allergic complaints <1 year 12 2.1%
History of severe allergic reaction 9 1.6%
Systemic disease 8 1.4%
Use of nasal corticosteroids 1 month before baseline 7 1.2%
Answer forms received after deadline of inclusion period 45 7.9%
Screening visit (n = 249)
Only grass pollen or tree pollen sensitization 81 32.5%
No sensitization detectable 75 30.1%
Sensitive to pet at home (confirmed by RAST) 60 24.1%
No informed consent 29 11.7%
Use of unallowed co-medication 4 1.6%BMC Family Practice 2008, 9:59 http://www.biomedcentral.com/1471-2296/9/59
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was male and 40% was aged 6–11 years. In the final
recruitment phase, 251 children were included in the
study. The distribution of age (6–11 years, p = 0.006) and
gender (boys 59%, p < 0.025) of the children included in
the present study is significantly different from those who
initially received the invitation letter.
Discussion
This is an ongoing randomized double-blind placebo-
controlled trial to establish the efficacy of sublingual
immunotherapy with house dust mite allergen in children
in primary care. Because the effectiveness of SLIT is still
under discussion (mainly due to inconclusive quality/
methodology of the published trials), the present long-
term study is expected to provide useful information
about SLIT with house dust mite allergen in primary care.
Although the distribution of age and gender of the partic-
ipating children is significantly different from those con-
tacted in the first recruitment phase, the difference is
relatively small and age and gender groups are adequately
represented; therefore, this difference should not affect
the generalizability of the results of the trial.
Table 3: Baseline characteristics of the included children
Total
(n = 251)
Percentage
Gender
Male 149 59.4%
Female 102 40.6%
Age
Mean (SD) in years: 11.8 (3.0)
6–11 years 122 48.6%
12–17 years 129 51.4%
Physical characteristics
Weight in kg: mean (SD) 47.5 (15.3)
Height in cm: mean (SD) 154.6 (17.1)
Season with most complaints of allergy
Spring 35 13.9%
Autumn 14 5.6%
Spring and autumn/entire year 201 80.1%
Nasal symptoms (scale 0–12)
Telephone screening: mean (SD) 6.8 (2.1)
Screening visit in last 3 months: mean (SD) 5.8 (2.3)
Screening visit in last week: mean (SD) 4.5 (2.6)
Asthma
Asthma present 92 36.7%
Asthma medication 99 39.4%
Wheeze/breathless – ever 154 62.3%
Wheeze/breathless – last year 131 53.9%
Dry cough at night – last year 130 52.6%
Sensitization
One allergen (monosensitized for HDM) 58 23.1%
Two allergens 67 26.7%
Three allergens 72 28.7%
Four allergens 54 21.5%
Sensitization to both HDM and
Grass pollen 179 71.3%
Tree pollen 108 43.0%
Cat dander 85 33.9%BMC Family Practice 2008, 9:59 http://www.biomedcentral.com/1471-2296/9/59
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Strengths and weaknesses
The importance of the methodology and quality of immu-
notherapy trials has been documented. [19] The present
study has a baseline assessment and complies with other
recommendations: i.e. placebo-controlled, double-blind,
randomized, adequate sample, sufficient duration of
treatment, patients selected according to predefined clini-
cal criteria, and clearly defined primary and secondary
outcomes.
Most related studies have been performed in a hospital
setting, [20,21] so that the results may not be applicable
to the general population. Therefore, our study is
designed to evaluate – in a primary care setting – the effi-
cacy and safety of SLIT in children and adolescents with
house dust mite-induced allergic rhinitis.
The ARIA guidelines propose that SLIT can be adminis-
tered to young patients if these children are carefully
selected with rhinitis, conjunctivitis and/or asthma caused
by pollen and mite allergy. [13] By recruiting young chil-
dren from a primary care setting (according to our meth-
odology) the included children will meet this
recommendation.
Most earlier studies failed to report on the phase prior to
randomization, whereas the present study reports the rea-
sons given not to participate and possible selection bias.
According to the WAO Task Force, the ideal efficacy study
of specific allergen immunotherapy should be performed
in monosensitized patients or in patients concomitantly
sensitized to noncross-reacting allergens. [22] It is
reported that single-allergen-specific immunotherapy
may prevent sensitization to other airborne allergens in
monosensitized children. [1,3,23] In our study we
included both monosensitized and multisentized chil-
dren; the majority was multisensitized and only 23% was
monosensitized. We believe that this will increase the gen-
eralizability of the study results to a wider range of
patients.
Many clinical trials face recruitment problems and have to
approach many patients in order to include only a small
proportion. [24,25] In a survey of 78 studies in Dutch pri-
mary care, a median of 87% of planned patients was
recruited. [26] In the present study 98% of the target sam-
ple size was recruited.
Conclusion
Our study was designed in accordance with recent recom-
mendations for research on establishing the efficacy of
sublingual immunotherapy; 98% of the target sample size
was reached. This study is expected to provide useful
information on the position of SLIT with house dust mite
allergen in primary care; results on the efficacy and safety
of SLIT should be available by 2010.
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